🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Medicamen Biotech Limited MEDICAMEQ NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.medicamen.com
Company Profile ↓
₹237.40
-39.02% 1Y
Mkt Cap₹321.98 Cr
P/E32.88
P/B1.01
Div. Yield0.41%
52W High₹415.95
52W Low₹223.30
Book Value₹203.17
EPS (TTM)₹7.22

Company Overview

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 12.0% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 32.9, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

  • Mar 2026 Revenue of ₹197.77 Cr (+21.7% YoY); net profit ₹9.64 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +21.7%, earnings +35.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.0%, profit CAGR -13.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.97%
1 Year:21.67%

Compounded Profit Growth

5 Years:-13.40%
1 Year:35.64%

Stock Price Performance

1 Year:-39.02%
6 Months:-40.68%
3 Months:-4.58%
1 Month:+5.39%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 7% of range
₹223.30 ₹415.95
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)44.56 · Neutral
Price Performance
1M+5.39%
3M-4.58%
6M-40.68%
1Y-39.02%
Valuation vs Sector

P/E of 32.88 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 12.0% over 5 years.

CONS

  • Earnings shrank at -13.4% CAGR over 5 years.
  • Trading 42.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
32.88
Industry PE
39.97
Forward P/E est.
24.24
PEG Ratio
-
Book Value
₹203.17
Price to Book
1.01
P/S
1.60
EV/EBITDA
13.04
Dividend Yield
0.41%

Growth (CAGR)

Revenue 5Y
11.97%
Profit 5Y
-13.40%
Revenue (YoY)
21.67%
Earnings (YoY)
35.64%

Profitability & Returns

ROCE
5.45%
ROE
3.50%
ROA
2.59%
Profit Margin
4.88%
Op Margin
6.25%
Gross Margin
48.54%
EPS (Latest Qtr)
₹3.28
EPS (TTM)
₹7.22

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
1.75
Current Ratio
2.54
Debt
₹47.78 Cr
Total Assets
₹371.99 Cr
Current Assets
₹223.73 Cr
Working Capital
₹135.81 Cr

Ownership

Promoter Holding
62.97%
Chg in Prom Hold
22.51%
FII / Inst Holding
0.00%
Chg in FII Hold
-0.10%

Financial Snapshot

Enterprise Value
₹321.98 Cr
Total Revenue (TTM)
₹197.77 Cr
EBITDA
₹22.70 Cr
Free Cash Flow
₹-37.95 Cr
Operating Cash Flow
₹-33.17 Cr
Shares Outstanding
₹1.36 Cr
Gross Margin
48.54%
Payout Ratio
13.85%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MEDICAMEQ Medicamen Biotech Limited NSEPHARMA 237.40 32.88 ₹321.98 Cr 0.41% 5.45% 3.50% 11.97% -13.40%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 38.67 Cr41.94 Cr43.54 Cr46.50 Cr47.32 Cr43.05 Cr--29.61 Cr43.04 Cr47.17 Cr46.91 Cr60.65 Cr
Cost of Revenue --------13.76 Cr22.71 Cr23.15 Cr23.71 Cr32.20 Cr
Gross Profit --------15.85 Cr20.33 Cr24.02 Cr23.20 Cr28.45 Cr
Operating Expenses 32.18 Cr34.99 Cr38.89 Cr41.60 Cr41.57 Cr39.60 Cr--17.94 Cr17.52 Cr20.72 Cr20.65 Cr24.74 Cr
Operating Income 4.87 Cr5.26 Cr2.83 Cr3.10 Cr3.98 Cr1.68 Cr---2.09 Cr2.81 Cr3.30 Cr2.55 Cr3.71 Cr
EBITDA 6.49 Cr6.95 Cr4.65 Cr4.90 Cr5.75 Cr3.45 Cr--3.62 Cr5.09 Cr5.53 Cr4.91 Cr7.18 Cr
Interest Expense 86.00 L96.00 L91.00 L65.00 L1.89 Cr71.00 L--64.99 L1.15 Cr98.89 L97.20 L38.30 L
Pretax Income 4.36 Cr4.68 Cr2.47 Cr3.28 Cr2.66 Cr1.56 Cr--2.49 Cr2.13 Cr2.68 Cr2.11 Cr5.06 Cr
Tax Provision 58.99 L73.99 L98.01 L1.25 Cr60.99 L76.00 L--62.66 L53.05 L56.86 L47.62 L61.27 L
Net Income 3.77 Cr3.95 Cr1.47 Cr2.03 Cr2.04 Cr80.00 L--2.42 Cr2.15 Cr2.67 Cr1.63 Cr3.86 Cr
Diluted EPS 3.073.301.191.901.681.06--1.471.181.561.213.28

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 123.00 Cr125.00 Cr113.00 Cr-140.87 Cr179.31 Cr162.55 Cr197.77 Cr
Cost of Revenue ----85.99 Cr109.55 Cr84.62 Cr101.77 Cr
Gross Profit ----54.88 Cr69.76 Cr77.93 Cr96.00 Cr
Operating Expenses 105.00 Cr106.00 Cr93.00 Cr-35.99 Cr52.35 Cr71.14 Cr83.63 Cr
Operating Income 15.00 Cr18.00 Cr17.00 Cr-18.89 Cr17.40 Cr6.79 Cr12.37 Cr
EBITDA 17.00 Cr20.00 Cr20.00 Cr-26.33 Cr24.57 Cr20.10 Cr22.70 Cr
Interest Expense 1.00 Cr1.00 Cr2.00 Cr-2.92 Cr4.40 Cr3.16 Cr3.50 Cr
Pretax Income 18.00 Cr18.00 Cr16.00 Cr-17.05 Cr13.08 Cr9.88 Cr11.98 Cr
Tax Provision 5.58 Cr4.68 Cr4.16 Cr-2.32 Cr3.58 Cr3.32 Cr2.19 Cr
Net Income 12.00 Cr13.00 Cr12.00 Cr-14.84 Cr10.93 Cr7.11 Cr9.64 Cr
Diluted EPS 10.2810.889.93-11.738.635.167.22

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 137.00 Cr181.00 Cr194.00 Cr-278.52 Cr294.55 Cr297.15 Cr371.99 Cr
Current Assets ----163.36 Cr159.59 Cr164.55 Cr223.73 Cr
Cash & Equivalents ----20.78 Cr14.79 Cr3.76 Cr31.26 Cr
Inventory ----45.06 Cr59.38 Cr62.14 Cr70.08 Cr
Receivables ----65.26 Cr55.26 Cr68.90 Cr81.83 Cr
Total Liabilities ----85.10 Cr87.57 Cr84.10 Cr96.44 Cr
Current Liabilities ----82.57 Cr84.56 Cr78.16 Cr87.92 Cr
Long Term Debt ----86.96 L1.26 Cr3.73 Cr6.15 Cr
Total Debt 12.00 Cr11.00 Cr19.00 Cr-25.71 Cr31.11 Cr33.77 Cr47.78 Cr
Total Equity 87.00 Cr121.00 Cr133.00 Cr-193.41 Cr205.09 Cr211.86 Cr275.55 Cr
Shares Outstanding ----1.27 Cr1.27 Cr1.27 Cr1.36 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 4.00 Cr13.00 Cr13.00 Cr--6.29 Cr-6.74 Cr-8.16 Cr-33.17 Cr
Investing Cash Flow -15.00 Cr-37.00 Cr-18.00 Cr--5.88 Cr-5.56 Cr-1.40 Cr-3.04 Cr
Financing Cash Flow -4.00 Cr19.00 Cr6.00 Cr-29.13 Cr6.31 Cr-1.47 Cr63.72 Cr
Capital Expenditure -15.00 Cr-38.00 Cr-18.00 Cr--6.60 Cr-6.29 Cr-2.19 Cr-4.78 Cr
Free Cash Flow -11.00 Cr-25.00 Cr-5.00 Cr--12.89 Cr-13.03 Cr-10.35 Cr-37.95 Cr
Net Change in Cash -14.00 Cr-5.00 Cr1.00 Cr-16.95 Cr-5.99 Cr-11.03 Cr27.50 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----39.0%38.9%47.9%48.5%
Operating Margin % 12.2%14.4%15.0%-13.4%9.7%4.2%6.3%
Net Margin % 9.8%10.4%10.6%-10.5%6.1%4.4%4.9%
ROE % 13.8%10.7%9.0%-7.7%5.3%3.4%3.5%
ROCE % ----9.6%8.3%3.1%4.4%

Shareholding Pattern

Insiders
62.97%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDICAMEQ

Google News Sat, 01 Nov 2025

Earnings Not Telling The Story For Medicamen Biotech Limited (NSE:MEDICAMEQ) After Shares Rise 25% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPcGl6WGI5bC1PUkl6aFdoQS1NcEJVQy1SV3Z2ZWtHU0dfbGJlNzdJbzRVcDUwZFFfQWhRUUhDQkxuaWZRNUdBT3NZOHAtTnFVZkJyb0dCMFRQejhyNTIxTXhtTUxidzl6OEFGWkJWeDlNNXBXU3A0Qmllem9MZ1FtX1pZWi1MQlo5cGJkZn…

Google News Wed, 28 May 2025

VALIANTLAB Stock Price and Chart — NSE:VALIANTLAB - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1WaVRBTVJrR3p2dGtDVHMxbllHd3V5MXlsVmVLZW1wQ2R4cXQwZHZOcU03eUR4Ul9VSWVOYnpZLXFCLUVFM1dhMExOME9hczNqNFJTUHc0NUR6SXJ2aHQ4eg?oc=5" target="_blank">VALIANTLAB Stock Price and Chart — NS…

Google News Fri, 21 Jan 2022

Medicamen Biotech Share Price - Upstox

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE1SOHA2MjRIWVBLVXZ2dEtJSFhHNjNRVXBnODJhbkZYbHFTVElFc3U1UkNBMEpSWTFZRGU0NzlLTVE5R2hQVmhIcV9fdVB4dzlWeDBrMVQ3anFUd2dkLWkxeEFVNU52THFBdWhrSWdHQ2FsUQ?oc=5" target="_blank">Medicamen Bio…

MEDICAMEQ — Frequently Asked Questions

What is the current share price of Medicamen Biotech Limited (MEDICAMEQ)?

As of 2026-07-15 09:52 IST, Medicamen Biotech Limited (MEDICAMEQ) trades at ₹237.40 on NSE. Its 52-week range is ₹223.30 to ₹415.95.

What is the market capitalisation of MEDICAMEQ?

Medicamen Biotech Limited (MEDICAMEQ) has a market capitalisation of ₹321.98 Cr on NSE.

What is the P/E ratio of MEDICAMEQ?

MEDICAMEQ trades at a trailing price-to-earnings (P/E) ratio of 32.88. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.01.

Does MEDICAMEQ pay a dividend?

Medicamen Biotech Limited (MEDICAMEQ) currently offers a dividend yield of 0.41%.

What is the return on equity (ROE) of MEDICAMEQ?

MEDICAMEQ has a return on equity (ROE) of 3.50%. Its return on capital employed (ROCE) is 5.45%.

Is MEDICAMEQ a good stock to buy?

This page provides a data-driven analysis of Medicamen Biotech Limited (MEDICAMEQ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space